2 unknown, 1 active not recruiting, 1 not yet recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Deafness, Autosomal Recessive 39: new trials by email Literature Review of Deafness, Autosomal Recessive 39 trials Research Report on Deafness, Autosomal Recessive 39
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury KP-100IT - Acute Spinal Cord Injury (SCI) | Phase 3 | Not yet recruiting | Kringle Pharma, Inc. | 10 | 2026-07-31 | 2026-07-23 |
| Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar KP-100LI, Placebo - Vocal Fold Scar | Phase 3 | Active not recruiting | Kringle Pharma, Inc. | 62 | 2022-12-01 | 2026-07-06 |
| Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients NL003, Placebo - Peripheral Artery Disease | Phase 3 | Unknown | Beijing Northland Biotech. Co., Ltd. | 36 | 2022-07-29 | 2023-08-01 |
| Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury KP-100IT - Acute Spinal Cord Injury | Phase 3 | Unknown | Kringle Pharma, Inc. | 25 | 2020-07-13 | 2022-08-26 |
Peripheral Arterial Disease (1)
Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Peripheral Vascular Diseases (1) · Vascular Diseases (1)
Hepatocyte Growth Factor (2) · Saline Solution (1)
Kringle Pharma, Inc. (3) · Beijing Northland Biotech. Co., Ltd. (1)
Japan (3) · China (1)
Daichika Hayata (1) · Etsuro Hashimura (1)